First Patient Dosed at Ribocure Clinic
With the ambition to become a world-leading clinical oligonucleotide research company, Ribocure Pharmaceuticals AB has established Ribocure Clinic, to focus on high-quality Proof of Principle Ph2 studies. The clinic has now dosed its first patient in a Phase 2 study using the world’s first and most advanced hemostasis sparing anti-thrombotic siRNA drug, RBD4059. Ribocure Clinic, […]
